acute lymphoblastic | Acute lymphoblastic leukemia

Acute lymphoblastic leukemia

Abstract
Acute lymphoblastic leukemias (LAL) are identified by the presence of more than 20% blastic cells, expressing membrane molecules B or T (1). It is important to distinguish the negative acute lymphoblastic (LAL) myeloperoxidase (DFO) leukemias from positive DFO acute myeloid leukemias (LAM), the clinical, biological and therapeutic management of these patients being very different.


Acute lymphoblastic leukemia
Authors: N. M, PM Carli, M. Maynadié, X. Troussard
Description of the location studied
Definition in the different classifications:
ICD-O-2: Localization C 42.0, C 42.1, C 42.3, C 42.4
Morphology: M9821, M9826, M9827; Tumor behaviour/3
ICD-O-1 correspondence: 169.0, 169.1, 169.3 and 169.9
Morphology: M9821; Tumor behaviour/3
Correspondence in ICD-10: C 91.0
Acute lymphoblastic leukemias (LAL) are identified by the presence of more than 20%
of blastic cells expressing membrane molecules B or T (1). It is important to
Distinguishing acute leukemias lymphoblastic (LAL) myeloperoxidase (DFO) negative
Positive DFO Acute myeloid leukemias (LAM), clinical, biological management
And therapeutic of these patients being very different.
Frequency
Acute leukemias account for 41.5% of new cases of leukemia occurring in
2000 in France, an incidence rate of 4.3 in men and 3.2 in women (2). This
Figure does not distinguish between acute leukemias of lymphoid origin and those of origin
which are very different conditions on the pathophysiological plane but also
Epidemiological. In Côte-d'or, the incidence rate of acute lymphoblastic leukemias,
Standardized for the world population, is 1.6 on average between 1980 and 1997. As
This is indicated in tables 7 and 9 of the previous chapter, this analysis was carried out on
341 cases, of which 251 had died within 5 years of diagnosis.
Raw survival and relative survival
Gross survival was 51% at 1 year, 31% at 3 years and 25% at 5 years, while relative survival
Was 58%, 32% and 26% respectively (table 1). Excess mortality, all ages,
Decreased steadily with the increase in time since the diagnosis (Figure 3).
Variation by Sex and age
Relative survival was slightly different in both men and women: at age 5, she was
29% in women and 24% in men (table 1 and Figure 1). Multivariate analysis
Increased the impression of a female advantage with a relative rate of 0.75 for women by
Report to men (table 7).
Survival was different depending on the age of diagnosis. 5-year survival was 35% for
The age class 15-44 years, but it was only 13% for subjects 75 years and over
(table 2 and Figure 2). The relative mortality rate increased almost linearly with age,
But this increase was almost limited to the first few months following the diagnosis
(Table 8 and figures 5, 6 and 7).